An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

NCT02398461 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Acute Relapsing

Interventions

DRUG: rHIgM22
DRUG: Placebo

Sponsor

Acorda Therapeutics

Collaborators

[object Object]